Serological tests: One more tool in India’s fight against Covid-19

  • Serological test will help in knowing the exact proportion of population which was actually infected with the virus
  • ICMR has already invited tenders for procurement of antibody testing kits which have been approved by US-FDA, EUA CE or NIV Pune

Srishti Choudhary
Updated29 Mar 2020, 07:06 PM IST
Sealed cassettes of Accula SARS-CoV-2 testing kits stand at a Mesa Biotech Inc. facility in San Diego, California, U.S., on Friday, March 27, 2020. Mesa Biotech's Accula SARS-CoV-2 Test, which gives diagnostic results in 30 minutes, has received emergency approval from the U.S. Food and Drug Administration (FDA) as a result of the novel coronavirus outbreak. Photographer: Bing Guan/Bloomberg
Sealed cassettes of Accula SARS-CoV-2 testing kits stand at a Mesa Biotech Inc. facility in San Diego, California, U.S., on Friday, March 27, 2020. Mesa Biotech’s Accula SARS-CoV-2 Test, which gives diagnostic results in 30 minutes, has received emergency approval from the U.S. Food and Drug Administration (FDA) as a result of the novel coronavirus outbreak. Photographer: Bing Guan/Bloomberg(Bloomberg)

As new infections continue to rise, India has begun preparations to start serological testing in the country, which may offer clues on how widely the new coronavirus has spread into the population and if people have developed immunity.

The Indian Council for Medical Research (ICMR) has already invited tenders for procurement of antibody testing kits which have been approved by US-FDA, EUA CE or NIV Pune. A tentative requirement of 10 lakh kits has been placed, which was later decreased to 5 lakh kits due to availability issues amid high demand from international manufactures.

While India has so far reported 979 positive cases so far, virologists the actual number could be higher, and serological tests could give real attack rates of the virus.

“Vast majority of people will have no symptoms. Younger the age more is the likelihood of such asymptomatic cases. But we cannot know these numbers until we do good quality antibody testing. It will help us know the exact proportion of population which was actually infected with the disease,” says Dr T Jacob John, former head of the Indian Council for Medical Research (ICMR)’s Centre for Advanced Research in Virology.

This is unlike the current nucleic-acid (RT-PCR) test done by laboratories. While a real time-Polymerase Chain Reaction (PCR) test is used to confirm Covid-19 in patients who are currently ill, the serological tests go a step further.

They allow scientists to even test seemingly healthy people who may have been infected with COVID-19 in the past but recovered without showing any symptoms. This is done by measuring the amount of antibodies from their blood samples.

“People, who have been acutely infected and recovered, have antibodies against the virus. Antibodies mean there is immunity. So, one is protected and not afraid of getting the virus. But, we do not know how long this immunity lasts, may be two years to ten years,” said Gagandeep Kang, clinical scientist at Christian Medical College, Vellore.

Our body releases two types of antibodies - IgM which get released usually three days after one starts showing symptoms and indicates the body is responding to an infection. And, IgM- is released much later and shows if the person was infected in the past and has recovered.

The government could use these tests to carry out sero-epidemiological studies and screen how much population has been exposed to the virus already and have developed immunity.

“It will enhance our preparedness. Imagine if we have to get factories running again and need to get people back to work, then in that case if we have the potential to identify people who can safely go out again, that would be helpful. But we must understand, that we need both the tests,” said Dr Anurag Aggarwal, Director of the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi.

This could even help define countries’ strategies in the worst-case scenario when healthcare workers start getting infected as cases surge. In that case, healthcare workers who have the antibodies and are not at risk can be put on the frontline - an approach being experimented by United Kingdom.

Some of the biggest serology is being done by China and South Korea. But, there are challenges regarding sensitivity, specificity and accuracy of these tests which limits their effectiveness for diagnosis.

But scientists also believe that it could help provide point-of care testing facilities, as the situation evolves and there is a surge in infected cases.

“If large-scale testing has to be done, serology may be the way. These are complementary tests which are less complex and helpful in urgent situations for they can be done locally,” said Dr Naveen Khanna, ICGEB International Centre for Genetic Engineering and Biotechnology (ICGEB).

Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:29 Mar 2020, 07:06 PM IST
Business NewsNewsIndiaSerological tests: One more tool in India’s fight against Covid-19

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Adani Power share price

    523.80
    03:59 PM | 27 NOV 2024
    86.05 (19.66%)

    Bharat Electronics share price

    307.25
    03:57 PM | 27 NOV 2024
    9.45 (3.17%)

    Indian Oil Corporation share price

    138.95
    03:59 PM | 27 NOV 2024
    1.95 (1.42%)

    Adani Ports & Special Economic Zone share price

    1,199.75
    03:52 PM | 27 NOV 2024
    70.95 (6.29%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Federal Bank share price

    212.80
    03:59 PM | 27 NOV 2024
    -0.75 (-0.35%)

    Laurus Labs share price

    544.30
    03:29 PM | 27 NOV 2024
    -1.95 (-0.36%)

    Piramal Enterprises share price

    1,190.25
    03:41 PM | 27 NOV 2024
    -7.1 (-0.59%)

    Wipro share price

    582.70
    03:56 PM | 27 NOV 2024
    -6.35 (-1.08%)
    More from 52 Week High

    Prestige Estates Projects share price

    1,630.55
    03:29 PM | 27 NOV 2024
    -75.15 (-4.41%)

    Rainbow Childrens Medicare share price

    1,580.05
    03:29 PM | 27 NOV 2024
    -63.95 (-3.89%)

    EPL share price

    264.90
    03:47 PM | 27 NOV 2024
    -8.75 (-3.2%)

    Fortis Healthcare share price

    645.35
    03:41 PM | 27 NOV 2024
    -19.25 (-2.9%)
    More from Top Losers

    Engineers India share price

    201.45
    03:55 PM | 27 NOV 2024
    17.45 (9.48%)

    Aster DM Healthcare share price

    478.45
    03:40 PM | 27 NOV 2024
    38.7 (8.8%)

    ADANI WILMAR share price

    314.90
    03:59 PM | 27 NOV 2024
    24.55 (8.46%)

    BHARAT DYNAMICS share price

    1,118.20
    03:52 PM | 27 NOV 2024
    85.95 (8.33%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      77,245.00-1,310.00
      Chennai
      77,251.00-1,310.00
      Delhi
      77,403.00-1,310.00
      Kolkata
      77,255.00-1,310.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.90/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts